CNC Quote, Financials, Valuation and Earnings

Clover Health Investments has a net margin of 0.69% compared to Centene's net margin of -6.56%. Centene's return on equity of 12.3% beat Clover Health Investments's return on equity of -13.55%.

Centene has a consensus price target of $78.94, signalling upside risk potential of 36.83%. On the other hand Clover Health Investments has an analysts' consensus of $4.75 which suggests that it could grow by 38.48%. Given that Clover Health Investments has higher upside potential than Centene, analysts believe Clover Health Investments is more attractive than Centene.

Centene has a beta of 0.529, which suggesting that the stock is 47.066% less volatile than S&P 500. In comparison Clover Health Investments has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Centene has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Clover Health Investments offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Centene pays -- of its earnings as a dividend. Clover Health Investments pays out -- of its earnings as a dividend.

Centene quarterly revenues are $40.8B, which are larger than Clover Health Investments quarterly revenues of $337M. Centene's net income of $283M is higher than Clover Health Investments's net income of -$22.1M. Notably, Centene's price-to-earnings ratio is 9.25x while Clover Health Investments's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Centene is 0.19x versus 1.28x for Clover Health Investments. Usually stocks with elevated PS ratios are considered overvalued.

Elevance Health has a net margin of 0.69% compared to Centene's net margin of 4.47%. Centene's return on equity of 12.3% beat Elevance Health's return on equity of 14.03%.

Centene has a consensus price target of $78.94, signalling upside risk potential of 36.83%. On the other hand Elevance Health has an analysts' consensus of $505.55 which suggests that it could grow by 19.89%. Given that Centene has higher upside potential than Elevance Health, analysts believe Centene is more attractive than Elevance Health.

Centene has a beta of 0.529, which suggesting that the stock is 47.066% less volatile than S&P 500. In comparison Elevance Health has a beta of 0.773, suggesting its less volatile than the S&P 500 by 22.685%.

Centene has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Elevance Health offers a yield of 1.57% to investors and pays a quarterly dividend of $1.71 per share. Centene pays -- of its earnings as a dividend. Elevance Health pays out 25.22% of its earnings as a dividend. Elevance Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Centene quarterly revenues are $40.8B, which are smaller than Elevance Health quarterly revenues of $48.9B. Centene's net income of $283M is lower than Elevance Health's net income of $2.2B. Notably, Centene's price-to-earnings ratio is 9.25x while Elevance Health's PE ratio is 16.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Centene is 0.19x versus 0.53x for Elevance Health. Usually stocks with elevated PS ratios are considered overvalued.

Molina Healthcare has a net margin of 0.69% compared to Centene's net margin of 2.67%. Centene's return on equity of 12.3% beat Molina Healthcare's return on equity of 25.66%.

Centene has a consensus price target of $78.94, signalling upside risk potential of 36.83%. On the other hand Molina Healthcare has an analysts' consensus of $358.75 which suggests that it could grow by 14.07%. Given that Centene has higher upside potential than Molina Healthcare, analysts believe Centene is more attractive than Molina Healthcare.

Centene has a beta of 0.529, which suggesting that the stock is 47.066% less volatile than S&P 500. In comparison Molina Healthcare has a beta of 0.701, suggesting its less volatile than the S&P 500 by 29.866%.

Centene has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Molina Healthcare offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Centene pays -- of its earnings as a dividend. Molina Healthcare pays out -- of its earnings as a dividend.

Centene quarterly revenues are $40.8B, which are larger than Molina Healthcare quarterly revenues of $11.1B. Centene's net income of $283M is lower than Molina Healthcare's net income of $298M. Notably, Centene's price-to-earnings ratio is 9.25x while Molina Healthcare's PE ratio is 15.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Centene is 0.19x versus 0.43x for Molina Healthcare. Usually stocks with elevated PS ratios are considered overvalued.

UnitedHealth Group has a net margin of 0.69% compared to Centene's net margin of 5.74%. Centene's return on equity of 12.3% beat UnitedHealth Group's return on equity of 21.74%.

Centene has a consensus price target of $78.94, signalling upside risk potential of 36.83%. On the other hand UnitedHealth Group has an analysts' consensus of $564.00 which suggests that it could grow by 34.72%. Given that Centene has higher upside potential than UnitedHealth Group, analysts believe Centene is more attractive than UnitedHealth Group.

Centene has a beta of 0.529, which suggesting that the stock is 47.066% less volatile than S&P 500. In comparison UnitedHealth Group has a beta of 0.607, suggesting its less volatile than the S&P 500 by 39.293%.

Centene has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UnitedHealth Group offers a yield of 2.01% to investors and pays a quarterly dividend of $2.10 per share. Centene pays -- of its earnings as a dividend. UnitedHealth Group pays out 52.29% of its earnings as a dividend. UnitedHealth Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Centene quarterly revenues are $40.8B, which are smaller than UnitedHealth Group quarterly revenues of $109.6B. Centene's net income of $283M is lower than UnitedHealth Group's net income of $6.3B. Notably, Centene's price-to-earnings ratio is 9.25x while UnitedHealth Group's PE ratio is 17.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Centene is 0.19x versus 0.94x for UnitedHealth Group. Usually stocks with elevated PS ratios are considered overvalued.